We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
JAMA Oncology Patient Page |

Fertility and Cancer Treatment FREE

Gleneara E. Bates, MSW; Robert N. Taub, MD, PhD; Howard West, MD
JAMA Oncol. 2016;2(2):284. doi:10.1001/jamaoncol.2015.4143.
Text Size: A A A
Published online

The ability to have children in the future is one of the many worrisome issues patients face when diagnosed with cancer.


The strictly regulated processes that lead to conditions of fertilization and healthy development of an egg in the uterus require precise balance. Chemotherapy, hormonal therapies, targeted therapies, or irradiation involving the reproductive organs may disrupt the balance of hormonal influences or lead to DNA damage during egg or sperm development. For both men and women, effects of chemotherapy on fertility depend on the specific therapy given, the dose, and the patient’s age.


Many patients treated for cancer can preserve their fertility, especially if they have the option of delaying treatment for 2 to 4 weeks (without significant effect on their outcome) to pursue fertility preservation efforts.

Fertility Preservation for Women With Cancer

For those wishing to preserve options beyond adoption or surrogacy, treatment options for women with cancer include egg (oocyte) freezing, embryo freezing, and gonadotropin-releasing hormone (GnRH) treatment (ovarian suppression). Oocyte freezing, also known as oocyte cryopreservation, is an established method of preserving female fertility and an ideal approach for women without a current partner who want to preserve their fertility. Mature eggs are removed and frozen prior to fertilization with sperm. Such treatment takes 2 to 4 weeks to complete.

Embryo freezing, also known as embryo cryopreservation, is a more common and successful method of preserving fertility in women. It requires a sperm donor at the time that eggs are removed from a woman’s ovaries, and then in vitro fertilization (IVF). Embryos are then frozen until completion of treatment. This process also requires 2 to 4 weeks.

Since GnRH is a hormone that controls other hormones that regulate the menstrual cycle, continuous GnRH treatment during cancer therapy may protect the ovaries from damage by “tricking” the body to thinking it is pregnant, thus preventing ovulation and reducing the number of eggs harmed during treatment. This is still an experimental treatment.

Fertility Preservation for Men With Cancer

Sperm banking is currently the most effective method of preserving fertility for men. The process takes from 2 to 4 hours. Men are advised to bank sperm prior to receiving chemotherapy or radiotherapy because these treatments reduce fertility. Sperm are then frozen to be used later to fertilize an egg via artificial insemination (directly injecting sperm into the uterus) or IVF.

Discussions of fertility preservation options should include the patient, their spouse or significant other, the treating oncologist, and potentially a fertility specialist. It is helpful to review all options as early as possible when developing a treatment plan, which should include referral to a sperm bank or egg/embryo preservation facility when appropriate. Fortunately, many patients who wish to have children after being treated for cancer are able to do so.


Section Editor: Howard (Jack) West, MD.
The JAMA Oncology Patient Page is a public service of JAMA Oncology. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA Oncology suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call (312) 464-0776.

Published Online: January 28, 2016. doi:10.1001/jamaoncol.2015.4143.

Conflict of Interest Disclosures: None reported.




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles